Prospective, randomized, controlled animal study.
SETTING: Experimental laboratory.
SUBJECTS: Male Sprague-Dawley rats weighing 350-500 g.
INTERVENTIONS: MEASUREMENTS AND MAIN RESULTS: Bronchoalveolar lavage fluid was recovered from the airway of rats after exposure to 95%
oxygen and
tumor necrosis factor-alpha for 6 hrs under
ventilator support. Neutrophils in lavage fluid were isolated and examined for the
inducible nitric oxide synthase expression by flow-cytometric assay.
Tumor necrosis factor-alpha and
interleukin-1 beta in lavage fluid were measured by
enzyme-linked
immunosorbent assay. The percentage of neutrophils in bronchoalveolar fluid was significantly higher in rats exposed to
hyperoxia +
tumor necrosis factor-alpha (29.7 +/- 12.5%) compared with rats with
hyperoxia (16.3 +/- 1.2%),
tumor necrosis factor-alpha (4.2 +/- 1.1%), or room air (5.0 +/- 1.8%) alone (p <.05). Rats exposed to
hyperoxia +
tumor necrosis factor-alpha had significantly higher concentrations of
inducible nitric oxide synthase of neutrophils (350.1 +/- 75.7 mean fluorescence intensity), compared with rats with
hyperoxia (64.9 +/- 1.6 mean fluorescence intensity),
tumor necrosis factor-alpha (102.6 +/- 15.3 mean fluorescence intensity), or room air (111.2 +/- 25.8 mean fluorescence intensity) alone (p <.05). Rats exposed to
hyperoxia +
tumor necrosis factor-alpha significantly produced higher concentrations of
tumor necrosis factor-alpha and
interleukin-1 beta, compared with rats with
tumor necrosis factor-alpha,
hyperoxia, or room air alone.
Hyperoxia +
tumor necrosis factor-alpha also significantly increased growth-related oncogene/
cytokine-induced neutrophil
chemoattractant (GRO/CINC)-1 in bronchoalveolar fluid, compared with those receiving
tumor necrosis factor-alpha alone,
hyperoxia alone, or room air alone.
L-NAME significantly enhanced the percentage of neutrophil recovery and the production of
tumor necrosis factor-alpha,
interleukin-1 beta, and GRO/CINC-1 in airways compared with the corresponding
hyperoxia +
tumor necrosis factor-alpha treatment alone.
CONCLUSIONS: